AMRN News and Press, Amarin Corporation plc

2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript

2024-07-31 12:28:03 ET Amarin Corporation plc (AMRN) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Aaron Berg – President and Chief Executive ...

2024-07-31 07:07:16 ET More on Amarin Amarin Q2 2024 Earnings Preview Amarin partner EddingPharm receives approval for VASCEPA in China Seeking Alpha’s Quant Rating on Amarin Historical earnings data for Amarin Financial information for Amarin ...

Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...

2024-07-30 12:30:02 ET More on Amarin Amarin partner EddingPharm receives approval for VASCEPA in China Amarin falls on CEO exit and Vascepa coverage update Seeking Alpha’s Quant Rating on Amarin Historical earnings data for Amarin Financial in...

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...

2024-07-08 08:40:12 ET More on Amarin Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript Amarin Corporation: Small Signs Of Recovery May Not Be Enough Amarin falls on CEO exit and Vascepa coverage update Amarin Q1 2024 Earnings Preview See...

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...

2024-06-04 11:10:56 ET More on Amarin Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript Amarin Corporation: Small Signs Of Recovery May Not Be Enough Amarin Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Amarin Historical...